Literature DB >> 24120607

Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.

Roberto Sartori1, Laura Candiotto1, Marco Ruggeri2, Giuseppe Tagariello1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24120607      PMCID： PMC3934286          DOI： 10.2450/2013.0135-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  5 in total

1.  Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.

Authors:  Andrea Piccin; Giovanni Amaddii; Fabrizio Natolino; Atto Billio; Sergio Cortelazzo
Journal:  Blood Transfus       Date:  2013-04-17       Impact factor: 3.443

2.  Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.

Authors:  Gregory Cheng; Mansoor N Saleh; Claus Marcher; Sandra Vasey; Bhabita Mayer; Manuel Aivado; Michael Arning; Nicole L Stone; James B Bussel
Journal:  Lancet       Date:  2010-08-23       Impact factor: 79.321

3.  Romiplostim or standard of care in patients with immune thrombocytopenia.

Authors:  David J Kuter; Mathias Rummel; Ralph Boccia; B Gail Macik; Ingrid Pabinger; Dominik Selleslag; Francesco Rodeghiero; Beng H Chong; Xuena Wang; Dietmar P Berger
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

4.  A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.

Authors:  Mehdi Khellaf; Jean-François Viallard; Mohamed Hamidou; Stéphane Cheze; Françoise Roudot-Thoraval; François Lefrere; Olivier Fain; Sylvain Audia; Jean-François Abgrall; Jean-Marie Michot; Charles Dauriac; Sophie Lefort; Emmanuel Gyan; Mathilde Niault; Jean-Marc Durand; Laetitia Languille; David Boutboul; Philippe Bierling; Marc Michel; Bertrand Godeau
Journal:  Haematologica       Date:  2013-02-26       Impact factor: 9.941

5.  Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.

Authors:  Francesco Zaja; Marta Lisa Battista; Maria Teresa Pirrotta; Salvatore Palmieri; Michela Montagna; Nicola Vianelli; Luciana Marin; Margherita Cavallin; Monica Bocchia; Marzia Defina; Micaela Ippoliti; Felicetto Ferrara; Francesca Patriarca; Maria Antonietta Avanzini; Mario Regazzi; Michele Baccarani; Miriam Isola; Franca Soldano; Renato Fanin
Journal:  Haematologica       Date:  2008-04-09       Impact factor: 9.941
  5 in total
  3 in total

1.  Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.

Authors:  Fabian Depré; Nasra Aboud; Beate Mayer; Abdulgabar Salama
Journal:  Blood Transfus       Date:  2017-01-25       Impact factor: 3.443

2.  Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia.

Authors:  Yeo-Kyeoung Kim; Seung-Sin Lee; Sung-Hoon Jeong; Jae-Sook Ahn; Deok-Hwan Yang; Je-Jung Lee; Hyeoung-Joon Kim
Journal:  Blood Res       Date:  2015-03-24

3.  Mitigation of total body irradiation-induced mortality and hematopoietic injury of mice by a thrombopoietin mimetic (JNJ-26366821).

Authors:  Vidya P Kumar; Gregory P Holmes-Hampton; Shukla Biswas; Sasha Stone; Neel Kamal Sharma; Bernadette Hritzo; Mary Guilfoyle; Gary Eichenbaum; Chandan Guha; Sanchita P Ghosh
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.996
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.